Alvotech (NASDAQ:ALVO – Get Free Report) and Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.
Profitability
This table compares Alvotech and Alnylam Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alvotech | -36.31% | -11.92% | -11.73% |
| Alnylam Pharmaceuticals | 15.26% | 84.93% | 14.30% |
Risk and Volatility
Alvotech has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alvotech | 2 | 2 | 4 | 0 | 2.25 |
| Alnylam Pharmaceuticals | 0 | 5 | 17 | 2 | 2.88 |
Alvotech currently has a consensus price target of $7.50, suggesting a potential upside of 41.78%. Alnylam Pharmaceuticals has a consensus price target of $376.67, suggesting a potential upside of 51.47%. Given Alnylam Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Alvotech.
Valuation and Earnings
This table compares Alvotech and Alnylam Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alvotech | $491.95 million | 3.25 | $27.92 million | ($0.61) | -8.67 |
| Alnylam Pharmaceuticals | $3.71 billion | 8.96 | $313.75 million | $5.38 | 46.22 |
Alnylam Pharmaceuticals has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Alnylam Pharmaceuticals beats Alvotech on 15 of the 15 factors compared between the two stocks.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
